Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.

Abstract: It has been found that an extracellular polypeptide derived from Akkermansia municiphila is capable of modulating and/or promoting gut mucosal immune system function and/or maintaining and/or restoring metabolic status and/or increasing the physical integrity of the gut mucosal barrier in a mammal. The polypeptide or host cells including such polypeptide may be employed to prevent and/or treat a variety of conditions that benefit from an increased physical integrity of the gut mucosal barrier and/or an improved gut mucosal immune system function and metabolic status.

Abstract: The present invention relates to pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of pasteurized Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

Abstract: A modified vesicular stomatitis virus glycoprotein (VSV-G) that includes at least one peptide, preferably an antigen or fragment thereof, nucleic acid sequence coding therefor, and vectors containing the nucleic acid sequence. Also vaccines and methods for the treatment of a disease or condition, in particular a cancer or an infectious disease.

Abstract: According to an embodiment a method is disclosed for establishing a Multipath TCP connection comprising a first and second TCP connection between a client and a server. The client performs the steps of: sending a synchronization segment to the server indicative for a request to establish the first and second TCP connection, receiving a synchronization and acknowledgement segment from the server, establishing the first and second TCP connections, sending an acknowledgment segment to the server in order for the server to establish the first and second TCP connection.

Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.

Abstract: According to a first aspect, the invention relates to a device (10) for electrochemically releasing a composition and comprising: one working electrode (30) comprising an electroactive conjugated polymer (40) containing or doped with said composition, a counter electrode (50), and a reference electrode (60). The device (10) is characterized in that it comprises electrical means (95, 100; 320; 165, 180) connected to the working electrode (30) and to the counter electrode (50) for obtaining at said working electrode (30) at least one composition releasing sequence (65) with respect to said reference electrode (60), each composition releasing sequence (65) comprising: a first voltametric pulse (70), followed by a rest period (80) during which no current is able to flow through said working electrode (30), followed by a second voltametric pulse (90), followed by an intermediate period (160) during which no current is able to flow through said working electrode (30).

Abstract: An example device includes a processor configured to receive a plurality of voltage values corresponding to voltage nodes in a first portion of a power system and determine, for each voltage node, a respective value of first and second voltage-constraint coefficients. The processor is also configured to receive a power value corresponding to a connection point of the first portion of the power system with a second portion of the power system and determine for the connection point, a respective value of first and second power-constraint coefficients. The processor is also configured to cause at least one energy resource connected to the first portion of the power system to modify an output power of the at least one energy resource based on the value of the first and second voltage-constraint coefficients for each voltage node and the value of the first and second power-constraint coefficients.

Abstract: The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition with procoagulant cells and at least one factor Xa inhibitor, preferably rivaroxaban, as well as at least one thrombin inhibitor, preferably bivalirudin.

Abstract: A positron emission tomography (PET) radiotracer for imaging lactate uptake, wherein the tracer is a [18F]-labelled lactate derivative. Also, a process for the radiosynthesis of the [18F]-labelled lactate derivative. Further, the use of the [18F]-labelled lactate derivative for imaging lactate uptake in living cells, especially in humans.

Abstract: The present invention relates to a two-degree-of-freedom planar rehabilitating, monitoring and/or evaluating device comprising a first guiding mechanism (2), a second guiding mechanism (3), substantially parallel to the first guiding mechanism (2), a third guiding mechanism (4), substantially perpendicular to the first and second guiding mechanisms (2, 3), and an end-effector (5), wherein the third guiding mechanism (4) is connected to the first and second guiding mechanisms (2, 3), and wherein the end-effector (5) is connected to the third guiding mechanism (4). The present invention also relates to a two-degree-of-freedom planar rehabilitating, monitoring and/or evaluating interactive device adapted for rehabilitation, monitoring and/or assessment of the upper limbs of a subject, comprising said device.

Abstract: A device (100) for the excision of a heart valve via a percutaneous route having a proximal (20) and distal (30) end, comprising an expandable cutting instrument, ECI, that forms a receptacle in the open configuration for receiving, compacting and containing the excised heart valve, an expandable cutting block, ECB, and a displacement mechanism (5, 6) for adjusting the distance between the ECI and the ECB (70).

Abstract: A device (100) is presented for excision of a heart valve comprising a first (120) and second (140) clamping element in mutual sliding relation, each having an annular clamping surface (122, 142) which annular clamping surfaces (122, 142) mutually co-operate to form an annular clamping region (166) configured for clamping a heart valve annularly, and a slidable cutting element (160) slidable and rotatable with respect to the annular clamping region (166) configured to circularly excise the heart valve, wherein the slidable cutting element (160) is displaceable within an annulus of the annular clamping zone region (166).

Abstract: A data transfer connection between a device and another device can be established using a basic protocol having a multipath extension that allows for the data transfer connection to use several different paths in parallel. In establishing the data transfer connection, an intermediate device receives a connection request from the device. This connection request comprises an indication that the device is capable of handling the multipath extension. In addition, the connection request comprises an identification of the other device with which the data transfer connection is to be established. The intermediate device then determines whether the other device is capable of handling the multipath extension, or not. The intermediate device establishes the data transfer connection in accordance with the multipath extension if the other device is capable of handling the multipath extension.

Abstract: According to an embodiment a method is disclosed for establishing a Multipath TCP connection comprising a first and second TCP connection between a client and a server. The client performs the steps of: sending a synchronization segment to the server indicative for a request to establish the first and second TCP connection, receiving a synchronization and acknowledgement segment from the server, establishing the first and second TCP connections, sending an acknowledgment segment to the server in order for the server to establish the first and second TCP connection.

Abstract: The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one antithrombin activator, preferably unfractionated heparin, as well as at least one thrombin inhibitor, preferably bivalirudin.

Abstract: The present invention relates to an antibody binding to the transmembrane protein ‘glycoprotein A repetitions predominant’ (GARP) in the presence of TGF-? and uses thereof.

Abstract: The present invention relates to a method for assessing, evaluating and/monitoring the purity of a mesenchymal stem cells preparation, in particular of an adipose stem cells preparation, comprising measuring the expression level of at least one growth factor.

Abstract: A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, ?-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.

Abstract: In an image sensor, a front-end circuit provides an output signal indicative of the amount of light in response to at least one input signal. The front-end circuit includes a transistor having a threshold voltage that affects a relationship between the output signal and the level of the detection quantity. This transistor has a biasing node via which a biasing voltage can be applied to a semiconductor region that affects the threshold voltage of the transistor. A replica of the front-end circuit receives at least one defined input signal, among which is a substitute of the detection quantity having a defined level. The replica is arranged in a control loop that controls the biasing voltage that is applied to the biasing node in the replica, so that the replica provides a defined output signal. This biasing voltage is then also applied to the biasing node in the front-end circuit.